WHY CHOOSE EXO-NET?
The EXO-NET matrix has the following features that make it a unique universal technology to facilitate the development of a range of exosome-based liquid biopsy applications:
Customizable for use with any sample: serum, plasma, whole blood, saliva, urine and cell culture medium.
Highly specific to the target
Low non-specific binding + Enhanced signal-to-noise
Adaptable to most existing detection technologies: potential for integration with emerging analytical and diagnostic technologies (PCR, ELISA, Flow cytometry, etc.)
Time to capture exosomes for downstream analysis is < 15 mins
Up to 1000x improved detection sensitivity over competitors
Combines two separation technologies: size exclusion and affinity binding for improved yield
Can be applied to mass screening strategies
EXO-NET outperforms other exosome capture methods and technologies.
EXO-NET is a transformational exosome capture technology.
EXO-NET technology allows for fast, accurate and efficient capture and isolation of exosomes from a range of fluids including cell culture medium and clinical specimens. The technology is highly scalable and is compatible with existing automated testing systems making it ideal for high volume clinical laboratory applications.
What is an EXO-NET?
EXO-NETs are provided as magnetic beads coated with a specialized matrix (known as a SIEN-NET™) that is designed to rapidly and specifically capture exosomes from cell culture medium and body fluids (plasma, urine,saliva, etc). The matrix contains nine different antibodies that bind to common exosome (or small extracellular vesicle) proteins, as well as containing pores that facilitate size exclusion of larger vesicles simultaneously.
A diagrammatic depiction of the molecular composition of the Molecular Net matrix coated on a magnetic bead. The matrix consists of ligands (represented as antibody molecules Y), linkers and spacers.
Exosomes are membrane bound, small (30-150nm) extracellular vesicles that are released from cells and contain a range of biomolecules.
A TRANSFORMATIONAL TECHNOLOGY FOR EXOSOME RESEARCH
Add EXO-NET beads to your sample (plasma, urine, saliva, cell culture fluid).
5-15 minutes later, wash EXO-NET particles three times with PBS on a magnetic holder.
Add your extraction buffer (for proteins, lipids, nucleic acids) to the exosomes captured on EXO-NET beads and perform your downstream assays.
EXO-NET IS AS SIMPLE AS...
FREQUENTLY ASKED QUESTIONS
Is EXO-NET compatible with my downstream assay?
EXO-NET has been validated for downstream protein and nucleic acid amplification techniques using the polymerase chain reaction. EXO-NET has also been validated for downstream protein and lipid analysis using mass spectometry or immunoassays.
What are EXO-NETs?
EXO-NETs are covalently-linked, multilayered, three-dimensional matrices, coated onto magnetic beads. The EXO-NET matrix comprises specific antibodies that bind to at least eight conserved exosomal proteins. Each EXO-NET bead has an enhanced, multi-layered surface area that facilitates the capture of multiple exosomes per bead. The EXO-NET matrix is covalently coated onto magnetic nanoparticles to allow rapid and easy downstream processing.
How do they work?
EXO-NETs are one specialized form of BARD1’s technology, referred to as SIEN-NETs. SIEN-NETs present a novel approach to producing a high capacity biomarker capture bead. The SIEN-NET matrix is a multilayered three dimensional matrix that contains an enhanced surface area as well as structural pores that effectively combines ligand capture and size exclusion properties that can be applied to isolate any biomarkers in a scalable, rapid and cost-effective method. This can be used as the sample preparation for a diagnostic liquid biopsy assay in high throughput commercial and hospital pathology laboratories, as well as for use in academic research studies.
Why are they better than standard antibody-based capture methods?
In order to overcome the limitation of single layers of antibody molecules coated onto magnetic beads that are standardly used for biomarker capture, we have developed a multilayered three-dimensional matrix comprising multiple antibody molecules with linkers to bind the capture molecules together and spacers to significantly enhance the surface area available for exosome binding.